Selected anti-cancer effects of Tan compounds in-vitro

Cancer typeCell linePathways/molecules alteredReferences
Astrocytoma Astrocytoma cells ↑Notch-1[97]
Breast cancer MDA-MB-231, MCF-7↓HIF-1α, ↓VEGF[102] [16]
Bladder cancer BCa ↓EMT[15]
Cervical cancer HPV positive CaSki ↓E6 and E7, ↑p53[19]
↓CYP2J2-mediated astemizole O-demethylation [19] [117]
Cervix carcinoma Stemness-like cancer cells ↓YAP mRNAs [98]
Colon cancer SW480↑E-cadherin, ↓vimentin and MMP-9[118]
CRC↓AMPK, ↑Skp2[52]
Esophageal cancer EC-109↑caspase-4, ↑CHO[24]
Gastric cancer AGS↓EGFR, ↓IGFR, ↓PI3K, ↓AKT, ↓mTOR, ↓NF-κB-p65, ↓COX-2 and MMP-2, -7 and -9 S, ↑p-p38, ↑p-JNK, ↑p53, ↑p21, ↑caspase-3 and caspase-8, ↑PARP
↓VEGFR, ↓HER2, ↓Ras, ↓Raf, ↓MEK, ↓ERK		[119] [58]
Gastric cancer SGC-7901↓Ki-67, ↓PCAN, ↓MMP-2, ↓MMP-9, ↓FOXM1, ↑P21[69]
SNU-638 & MKN1↑Bcl-2, ↓caspase-3, ↓p-STAT3[54] [37]
Glioma U251↓p-PI3K, ↓Bcl-2, ↓p-Akt, ↑Bax, ↑LC3B, ↑Beclin 1[37]
Leukaemia APLC/EBPβ[99]
Liver cancer HepG2↓CYP2J2 activity [117]
HepG2↑LDLR, ↑p53, ↓HNF-1α, ↓Nec-1, ↓PCSK9[53] [81]
Lung cancer A549↑Cleaved Caspase-3 and Bax, ↓VEGF, ↓VEGFR2, ↓p-PI3K, ↓p-Akt, ↓Bcl-2, ↓Caspase-3 protein [25] [26] [30] [31]
Melanoma A375↑Beclin-1, ↑LC3-II expression, ↓pPI3K, ↓p-AKT, ↓p-mTOR, ↓p-p7036k1[41]
Oral cancer SCC-9 squamous carcinoma ↑ROS, ↑Beclin 1, ↑Atg5[89] [90]
Ovarian cancer TOV-21G↑TRAIL-induced apoptosis, ↑DR5, ↑ROS-JNK-CHOP, ↑miR-205, ↑Bcl-2 ↓Mcl-1L, ↓PI3K, ↓AKT, ↓JNK[43] [45]
Osteosarcoma 143B↓Ki67, ↓PCNA[42]
MG-63↑Cleaved-PARP, ↑ROS, ↑Caspase-3, -8 and -9[96]
PCPC-3↓Beclin1, ↓LC3-II[32]
LNCaP↑maspin, ↑ARs [120]
PC12↓p-Akt, ↓p-ERK1/2, ↑p-FOXO3a, ↑c-Raf [121]

EMT: epithelial-mesenchymal transition; FoxM1: forkhead box M1; MMP-2: matrix metalloproteinase 2; MMP-9: matrix metalloproteinase 9